Physician profile
Marc E Lewis
NPI 1417022112
$1,553.65
in general payments reported to CMS, 2019-2025
23 companies · $14.12 in 2025
The $14.12 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $387 · 2020: $345 · 2021: $248 · 2022: $34.79 · 2023: $239 · 2024: $286 · 2025: $14.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.29 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $372.83 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $169.45 | 2019-2025 | Vaxneuvance, Gardasil 9, Capvaxive |
| Amgen INC. | $152.09 | 2019-2020 | |
| Glaxosmithkline, LLC. | $139.76 | 2019-2024 | Arexvy |
| Astrazeneca Pharmaceuticals Lp | $119.33 | 2019-2021 | |
| Pfizer INC. | $91.86 | 2019-2023 | |
| Abbvie INC. | $82.45 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $71.31 | 2019-2021 | |
| Novo Nordisk INC | $69.70 | 2019-2021 | |
| Lilly USA, LLC | $45.40 | 2019-2024 | Jardiance |
| Esperion Therapeutics, INC. | $31.66 | 2020-2021 | |
| Dexcom, INC. | $29.25 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $24.66 | 2024 | Cologuard Collection Kit |
| Boston Scientific Corporation | $23.27 | 2021 | |
| Seqirus USA INC | $19.50 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $18.32 | 2019 | |
| Electromed, INC. | $18.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.04 | 2022 | |
| Alkermes, INC. | $16.85 | 2023 | Vivitrol |
| Allergan, INC. | $16.39 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.36 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.33 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.